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Summary
 
We have previously shown that interferon and tumor necrosis factor noncytopathically abolish
hepatitis B virus (HBV) replication from the hepatocyte and kidney tubular epithelial cells in
vivo. Here we show that a persistent lymphocytic choriomeningitis virus (LCMV) infection is
cleared from the hepatocyte noncytopathically when the same cytokines are induced in the
liver by antigen-nonspecific stimuli. These results indicate that, like HBV, LCMV is also sus-
ceptible to intracellular inactivation by cytokine-induced antiviral mechanisms that are opera-
tive in the hepatocyte. In contrast, LCMV is not cleared from intrahepatic nonparenchymal
cells or splenocytes, indicating that, unlike the hepatocyte, these cells do not produce the fac-
tors required to inactivate LCMV. Antiviral mechanisms like these may have evolved to main-
tain the functional integrity of vital organs in the face of massive infection.
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C
 
ytokines appear to play an effector role in the antiviral
immune response during hepatitis B virus (HBV)
 
1
 
 in-
fection. Recently we have shown that HBV-specific CTLs
can abolish viral gene expression and replication in the liver
of HBV transgenic mice by noncytopathic mechanisms that
are mediated by IFN-
 
g 
 
and TNF-
 
a 
 
(1). Similar cytokine-
mediated antiviral events occur in these animals after the
administration of IL-12 (2) and also during unrelated hepa-
totropic infections with lymphocytic choriomeningitis vi-
rus (LCMV [3]), adenovirus (4), and CMV (4), which sup-
press HBV replication by inducing type I IFN as well as
IFN-
 
g
 
 and TNF-
 
a
 
. These results suggest that the intrahe-
patic cytokine profile of the antiviral immune response may
determine the outcome of HBV infection in humans, e.g.,
viral clearance versus viral persistence. In support of this
notion, we have recently shown that viral clearance coin-
cides with the kinetics of intrahepatic induction of IFN-
 
g
 
and TNF-
 
a
 
 and precedes the onset of hepatitis in chim-
panzees acutely infected with HBV (4a).
The relative contribution of cytodestructive versus cura-
tive functions of the immune response is less clear in the case
of other viral infections, including LCMV, the prototypic
noncytopathic virus that requires CD8
 
1
 
 T cells for clear-
ance (5). For example, perforin-deficient mice are unable
to clear LCMV (6, 7), although virus replication is less effi-
ciently controlled in mice that lack IFN-
 
g
 
 receptors (8) or
that have been treated with IFN-
 
g
 
–specific antibodies (9–11).
Additionally, persistent LCMV infection can be cleared by
very small numbers of adoptively transferred CTLs (12) and
in the absence of severe immunopathology (13). Conversely,
viral clearance does not occur when relatively high numbers
of IFN-
 
g
 
–deficient CTLs are passively transferred (14).
This study was undertaken to test whether the clearance
of persistent LCMV infection from liver and spleen ob-
served after adoptive transfer of LCMV-immune spleen
cells could be reproduced by the local induction of cyto-
kines known to control HBV replication (i.e., IFN-
 
g
 
,
TNF-
 
a
 
, and IFN-
 
a
 
/
 
b
 
). Intrahepatic and intrasplenic cy-
tokine induction was achieved in persistently LCMV–
infected mice by superinfection with a replication-deficient
adenovirus or by repetitive injections of IL-12. The results
indicate that LCMV can be eliminated from the hepato-
cytes in a cytokine-dependent, noncytopathic bystander
manner, but that other events, presumably killing, are
needed to eliminate LCMV from other cell types.
 
1
 
Abbreviations used in this paper:
 
 APP, acute phase protein; ARM, Armstrong
strain; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HBV, hepati-
tis B virus; LCMV, lymphocytic choriomeningitis virus; NP, nucleoprotein;
2
 
9
 
5
 
9
 
 OAS, 2
 
9
 
,5
 
9
 
-oligoadenylate synthetase; sALT, serum alanine amino-
transferase. 
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Materials and Methods
 
Mice
 
C57BL/6 and BALB/c mice were purchased from The Jackson
Laboratory or from our breeding colony at The Scripps Research
Institute.
 
Viruses and Infection of Mice
 
LCMV strain Armstrong (ARM) 53B, a clone triple plaque puri-
fied from ARM CA 1371 (15), was used in this study. Viral stocks
were prepared by growth in BHK-21 cells. Viral titers were mea-
sured by plaque assay as described (15). In brief, monolayers of Vero
cells were infected with different dilutions of mouse sera or tissue
homogenates, and plaques were counted 6 d later. To establish a
persistent infection, C57BL/6 and BALB/c mice were infected
within 24 h of birth by intracardiac inoculation of 10
 
3
 
 PFU of
LCMV ARM. LCMV-immune mice were obtained by injecting
8–10-wk-old mice intraperitoneally with 2 
 
3
 
 10
 
5
 
 PFU of LCMV
ARM. Immune mice were used at 
 
.
 
60 d after infection. BALB/c-
derived LCMV-immune splenocytes (5 
 
3
 
 10
 
7
 
 cells) were injected
intraperitoneally into persistently infected BALB/c mice that were
irradiated (350 rads) a few hours before transfer and killed at multi-
ple time points thereafter. A recombinant, replication-deficient ade-
novirus, designated Ad.CBlacZ, provided by Dr. James Wilson
(University of Pennsylvania Medical Center, Philadelphia, PA [16]),
was also used to infect LCMV-carrier BALB/c mice. Stocks of
Ad.CBlacZ were grown in 293 cells (17), and were purified by two
rounds of CsCl density centrifugation, as described previously (18).
Viral titers were determined by plaque assay on 293 cells, and a sin-
gle stock was used throughout this study. Mice were injected intra-
venously with 1.5 
 
3
 
 10
 
9
 
 PFU/mouse, a dose of Ad.CBlacZ known
to infect 100% of the hepatocytes and to cause a CD8-dependent
liver disease (4). Control mice were injected with the same volume
of saline. Animals were killed at multiple time points after infection.
 
IL-12
 
Recombinant murine IL-12 was provided by Dr. Maurice
Gately (Hoffmann-La Roche, Nutley, NJ). C57BL/6 mice were
injected intraperitoneally with IL-12 (1 
 
m
 
g/d/mouse). Control ani-
mals were injected with saline diluent (saline containing 1% serum)
only. Animals were killed 24 h after the last injection of IL-12, and
their sera, livers, and spleens were harvested for subsequent analyses.
 
RNA Analysis
 
Northern Blot Analysis.
 
Frozen tissues were mechanically pul-
verized, and RNA was extracted by the acid-guanidium phenol-
chloroform method (19). Total RNA (20 
 
m
 
g) was analyzed for
2
 
9
 
,5
 
9
 
-oligoadenylate synthetase (2
 
9
 
5
 
9
 
 OAS) and glyceraldehyde-
3-phosphate (GAPDH) expression by Northern blot as described
previously (3).
 
RNase Protection Assay.
 
The RNase protection assay for quan-
titation of mRNA was performed exactly as described (20). The
mouse IL-1
 
a
 
(B), mIL-1
 
b
 
(A), mIL-2(A), mIL-3(B), mIL-4(B),
mIL-5(C), mIL-6(B), mIFN
 
g
 
(B), mTNF
 
a
 
(A), mTNF
 
b
 
(A), and
mL32(A) subclones in the pGEM-4 transcription vector were de-
scribed in a previous report (20). The mCD4(IC), mCD3
 
g
 
(IC),
mCD8
 
a
 
(DM), and F480 subclones in the pGEM-4 vector were
described previously (1).
 
In Situ Hybridization.
 
This procedure was carried out exactly
as described (21). The 
 
33
 
P-labeled RNA probe used in this study
was prepared by transcription from the T7 promoter of plasmid
nucleoprotein (NP) Bluescript, a plasmid created by cloning the
1,164-bp BglII fragment from a cDNA of the LCMV ARM S
RNA segment (22) into the plasmid Bluescript KS (Stratagene,
Inc.). Transcription from the T7 promoter of pNP Bluescript
generates a single-stranded RNA probe complementary to the
viral NP mRNA and antigenomic sequence.
 
Table I.
 
sALT Activity and LCMV Titers in Serum, Liver, and Spleen
 
Treatment
Mouse
strain
No. of 
Mice
Time of
autopsy
sALT
(day 0)
sALT
(autopsy) Serum LCMV Liver LCMV Spleen LCMV
 
(PFU/ml) (PFU/g) (PFU/g)
 
Saline BALB/c 3 day 3 66 
 
6
 
 11 100 
 
6
 
 10 7.3 
 
6
 
 1.0 
 
3
 
 10
 
4
 
6.9 
 
6
 
 3.0 
 
3
 
 10
 
6
 
7.0 
 
6
 
 5.2 
 
3
 
 10
 
6
 
Saline BALB/c 3 day 24 63 
 
6
 
 15 56 
 
6
 
 35 2.6 
 
6 
 
0.1 
 
3
 
 10
 
4
 
1.1 
 
6
 
 0.4 
 
3
 
 10
 
7
 
1.2 
 
6
 
 0.7 
 
3
 
 10
 
7
 
Memory BALB/c 3 day 3 50 
 
6
 
 10 590 
 
6
 
 527 5.8 
 
6
 
 2.3 
 
3
 
 10
 
4
 
7.5 
 
6
 
 12 
 
3
 
 10
 
6
 
3.7 
 
6
 
 0.2 
 
3
 
 10
 
5
 
Memory BALB/c 3 day 7 52 
 
6
 
 11 953 
 
6
 
 826 1.1 
 
6
 
 0.2 
 
3
 
 10
 
4
 
,
 
400 6.1 
 
6
 
 5.0 
 
3
 
 10
 
4
 
Memory BALB/c 3 day 14 64 
 
6
 
 15 283 
 
6
 
 137 3.2 
 
6
 
 2.4 
 
3
 
 10
 
3
 
,
 
400 6.5 
 
6
 
 5.5 
 
3
 
 10
 
3
 
Memory BALB/c 3 day 24 65 
 
6
 
 14 63 
 
6
 
 20
 
,
 
400
 
,
 
400
 
,
 
400
Adenovirus BALB/c 4 day 3 63 
 
6
 
 14 80 
 
6
 
 14 8.6 
 
6
 
 3.5 
 
3
 
 104 6.3 6 3.3 3 106 1.8 6 0.7 3 107
Adenovirus BALB/c 4 day 7 60 6 10 2,485 6 739 2.9 6 1.7 3 105 3.9 6 1.5 3 106 1.8 6 0.7 3 107
Adenovirus BALB/c 4 day 14 54 6 12 2,085 6 521 9.1 6 2.7 3 104 1.0 6 13 3 107 1.0 6 5.0 3 107
Adenovirus BALB/c 4 day 21 63 6 11 612 6 795 6.3 6 2.7 3 104 1.9 6 26 3 106 1.4 6 4.2 3 107
Adenovirus BALB/c 4 day 24 58 6 14 97 6 63 3.3 6 1.9 3 104 4.4 6 47 3 106 1.2 6 5.4 3 107
Saline C57BL/6 3 day 4 67 6 16 70 6 27 1.3 6 8.7 3 104 3.1 6 23 3 106 1.7 6 13 3 106
IL-12 (1 mg 3 3) C57BL/6 5 day 4 60 6 3 78 6 16 2.1 6 1.3 3 104 4.8 6 35 3 106 1.1 6 8.5 3 106
Saline C57BL/6 6 day 11 49 6 13 76 6 22 2.7 6 1.0 3 104 9.2 6 6.8 3 106 2.6 6 20 3 106
IL-12 (1 mg 3 10) C57BL/6 8 day 11 54 6 19 140 6 68 8.4 6 11 3 104 2.7 6 17 3 106 3.7 6 28 3 106
sALT and PFU are expressed as mean 6 SEM.1557 Guidotti et al.
RNA PCR Assay for the Detection of LCMV ARM and the Vari-
ant Clone 13. Total liver RNA (1 mg) was reverse transcribed
into cDNA and amplified by PCR using LCMV glycoprotein–
specific primers exactly as described (23). Quantitation of LCMV
ARM and clone 13 RNA was carried out by densitometric anal-
ysis (NIH Image software) of the amplified PCR products after
MnlI digestion, gel electrophoresis, and ethidium bromide stain-
ing, exactly as described (23).
Biochemical and Histological Analysis of Liver Disease
Hepatocellular injury was monitored by measuring serum ala-
nine aminotransferase (sALT) activity (1). Results were expressed
as mean sALT activity 6 SEM. Tissue samples were fixed in 10%
zinc-buffered formalin (Anatek, Ltd.), embedded in paraffin, sec-
tioned (3 mm), and stained with hematoxylin and eosin as de-
scribed (1).
Immunohistochemical Analysis
The intracellular distribution of LCMV NP was analyzed by
immunohistochemical analysis based on a method described by
Surh et al. (24). 3-amino-9-ethyl carbazole (red) was used as col-
oring substrate for LCMV NP, exactly as described (3).
b-Galactosidase Histochemistry
The in vivo expression of b-galactosidase in the livers of
Ad.CBlacZ-infected animals was quantitated by 5-bromo-
4-chloro-3-indolyl-b-d-galactosidase (X-gal) histochemistry exactly
as described (4).
Results
Persistent LCMV Infection in C57BL/6 and BALB/c Mice.
C57BL/6 and BALB/c mice were infected at birth with
LCMV ARM as described in Materials and Methods. At
7–8 wk of age, all animals were bled and serum viral ti-
ters were analyzed by plaque assay. Mice with a serum titer
between 104 and 105 PFU/ml were selected, and 2–4 wk
later were used as recipients of saline, LCMV-immune
“memory” cells, adenovirus, or IL-12. Table I shows the
viral titers in serum, liver, and spleen of control BALB/c
and C57BL/6 mice that were killed at the indicated time
points after saline injection. The hepatic content of LCMV
RNA in the saline-injected controls was monitored by
Northern blot analysis (see Figs. 1, 5, and 7) and by in situ
hybridization analysis (see Figs. 2 A, 6 A, and 8 A) in which
hepatic LCMV RNA was detected in z30–40% of the
hepatocytes (Figs. 2 A, 6 A, and 8 A) and in nonparenchy-
mal cells in the hepatic sinusoids (Fig. 2 A, arrows). Next,
we monitored the hepatic content of mRNA for CD3,
CD4, CD8, various cytokines, and 2959 OAS (a marker of
IFN-a/b induction) in these control animals. In keeping
with the massive LCMV infection, high levels of 2959 OAS
mRNA were detected in the liver, illustrating that type I
IFN is not sufficient to clear LCMV from the organ. Fur-
thermore, all T cell markers and T cell–dependent cyto-
kines were absent, and only low levels of mRNA for the
monokines TNF-a, IL-1a, and IL-1b were detected (see
Figs. 1, 5, and 7), reflecting the absence of histological (Fig.
3 A) or biochemical (Table I) evidence of liver disease in
these persistently infected animals.
Clearance of persistent LCMV infection after adoptive
transfer of memory cells occurs very rapidly in the liver
without massive liver cell injury. Splenocytes derived from
mice that have cleared an acute LCMV infection (i.e.,
memory cells) are known to clear LCMV when injected
into persistently infected animals (5). To better understand
the mechanisms responsible for this effect, 2 3 107 BALB/c
LCMV-immune memory splenocytes were adoptively trans-
Figure 1. Intrahepatic LCMV, T cell marker, and cytokine gene ex-
pression after adoptive transfer of memory cells. Age- and serum LCMV
titer–matched BALB/c mice were injected intraperitoneally either with
saline or with 2 3 107 memory cells, and livers were harvested from mice
killed on days 3, 7, 14, and 24 after injection, as indicated. Northern blot
(NB) analysis (top panel) was performed with 20 mg of total liver RNA
from two representative mice per group. The membrane was hybridized
with 32P-labeled LCMV-, 2959 OAS– (a marker of IFN-a/b induction),
and GAPDH-specific DNA probes. Total hepatic RNA (10 mg) from the
same mice was also analyzed by RNase protection assay (RPA) for the
expression of various cytokine transcripts, and for the expression of CD3,
CD4, CD8, and F480, as indicated. The mRNA encoding the ribosomal
protein L32 was used to normalize the amount of RNA loaded in each
lane. The results of the plaque assay (PFU per gram) of individual liver
tissues are also indicated. ND, not detectable.1558 Noncytopathic Clearance of LCMV
ferred into 12 BALB/c mice, and groups of 3 mice were
killed on days 3, 7, 14, and 24 after transfer (Table I). Pre-
dictably, LCMV was undetectable on day 24 in serum,
liver, and spleen by plaque assay (Table I). Interestingly, the
viral titer dropped very rapidly in the liver (.6 logs in 4 d),
becoming undetectable by day 7 after memory cell transfer
(Table I). At this time point, viral RNA was also undetect-
able by Northern blot analysis of total liver RNA (Fig. 1).
However, traces of viral RNA remained detectable at day 7
in a few nonparenchymal cells that resemble endothelial
cells and biliary duct epithelial cells in the portal tracts (Fig.
2 B). Interestingly, these cells remained LCMV RNA–pos-
itive even at the latest time point examined (day 24; not
shown), suggesting that they are relatively resistant to viral
clearance. Along with LCMV RNA, LCMV NP was un-
detectable immunohistochemically in the hepatocytes by
Figure 2. Intrahepatic distribution of
LCMV RNA after adoptive transfer of
memory cells. The same livers described in
the legend to Fig. 1 were analyzed for the
expression of LCMV RNA by in situ
hybridization using a specific 33P-labeled
LCMV riboprobe. (A) Detection of hepatic
LCMV mRNAs in saline-injected control
mice. Note that most LCMV RNA is con-
tained in the hepatocytes compared with
nonparenchymal cells (arrows). (B). Detec-
tion of hepatic LCMV mRNAs in mice in-
jected with memory cells and killed at day
7. Note that LCMV RNA is no longer de-
tectable in the hepatocytes but remains in a
few nonparenchymal cells that resemble en-
dothelial cells and biliary duct epithelial cells
in the portal tracts (hematoxylin and eosin;
original magnification: 3600).
Figure 3. Histopathological features of viral hepatitis in the liver of mice after adoptive transfer of memory cells. Liver sections obtained from persis-
tently LCMV–infected mice killed at the indicated time points after injection of saline (A) or after adoptive transfer of memory cells (B and C) were
stained with hematoxylin and eosin as described in Materials and Methods. Note that the vast majority of the hepatic parenchyma is cytologically normal
in all panels. A few mononuclear cells are seen in rare portal tracts (PT) 3 d after transfer of memory cells (B) and, in addition to this, small, scattered
necroinflammatory foci (arrowheads) are detected in the hepatic parenchyma 7 d after transfer of memory cells (C). Original magnification: 3100.1559 Guidotti et al.
day 7 (not shown). Importantly, LCMV titer dropped much
more slowly (,2 logs in 14 d) in serum and spleen, al-
though LCMV was eventually cleared from these compart-
ments between days 14 and 24 (Table I). sALT activity (a
marker of hepatocellular necrosis [25]) reached values of
z600, z700, and z900 U/l at days 3, 5, and 7 (Table I),
respectively. After its peak at day 7, sALT activity returned
to normal levels (z60 U/l) between days 14 and 24 (Table
I). sALT activity was only modestly elevated in these mice,
compared with previously reported mouse models of liver
disease (26). In particular, by comparing these ALT profiles
with known standards (1), we estimate that no more than
5–10% of the hepatocytes were killed during the first week
after adoptive transfer, despite the fact that at least 30–40%
of hepatocytes were infected (Figs. 2 A, 6 A, and 8 A). This
notion is also supported by histological analysis of these liv-
ers, which shows that 3 and 7 d after transfer of memory
cells, the vast majority of the hepatic parenchyma is cyto-
logically normal (Fig. 3, B and C). At day 3, few mono-
nuclear cells are seen in portal tracts (PT), and at day 7 the
hepatic parenchyma contains small, scattered necroinflam-
matory foci (Fig. 3 C, arrowheads); and, in keeping with
the relatively mild liver disease, no liver cell regeneration
was observed at the peak of sALT activity (day 7; Fig. 3 C),
at which time LCMV RNA had disappeared from the
hepatocytes (Fig. 2 B). The kinetics of liver disease and the
kinetics of viral clearance coincided with the appearance of
T cell (especially CD8), macrophage, and cytokine (2959
OAS, IFN-g, TNF-a, IL-1a, and IL-1b) markers in the
liver (Fig. 1). It is noteworthy that the virus was cleared
much more slowly in the spleen despite the fact that the
same cytokines were induced with the same kinetics ob-
served in the liver (Fig. 4). Collectively, these results indi-
cate that hepatocytes have the capacity to clear LCMV very
rapidly, and this occurs in the presence of antiviral cyto-
kines and in the absence of a commensurate degree of cell
death. In contrast, the slower kinetics of clearance of LCMV
from nonparenchymal liver cells and from the spleen indi-
cate that these cells are relatively resistant to memory cell–
induced clearance.
Figure 4. Cytokine gene expression in the spleen of mice after adoptive
transfer of memory cells. Total RNA (10 mg) extracted from the spleen of the
same mice described in the legend to Fig. 1 was analyzed by RNase protection
assay (RPA) for the expression of various cytokine transcripts as indicated. The
mRNA encoding the ribosomal protein L32 was used to normalize the
amount of RNA loaded in each lane. The results of the plaque assay (PFU per
gram) of individual spleen tissues are also indicated. ND, not detectable. Un-
inf., uninfected.
Figure 5. Intrahepatic LCMV, T cell marker, and cytokine gene ex-
pression after adenovirus infection. Age- and serum LCMV titer–matched
BALB/c mice were injected intravenously either with saline or with 1.5 3
109 PFU of adenovirus (Ad.CBlacZ), and livers were harvested from mice
killed on days 3, 7, 14, 21, and 24 after injection, as indicated. Northern
blot (NB) analysis (top panel) was performed with 20 mg of total liver
RNA from two representative mice per group. The membrane was hy-
bridized with 32P-labeled LCMV-, 2959 OAS– (a marker of IFN-a/b in-
duction), and GAPDH-specific DNA probes. Total hepatic RNA (10 mg)
from the same mice was also analyzed by RNase protection assay (RPA)
for the expression of various cytokine transcripts, and for the expression
of CD3, CD4, CD8, and F480, as indicated. The mRNA encoding the
ribosomal protein L32 was used to normalize the amount of RNA loaded
in each lane. The results of the plaque assay (PFU per gram) of individual
liver tissues are also indicated.1560 Noncytopathic Clearance of LCMV
Clearance of Persistent LCMV Infection from the Hepatocyte
after Adenovirus Infection or IL-12 Administration. To mon-
itor the antiviral effect of the induction of these cytokines
in the liver of mice persistently infected with LCMV, 20
BALB/c mice were infected intravenously with a dose (1.5 3
109 PFU) of a recombinant, replication-deficient adenovi-
rus (Ad.CBlacZ) that we have previously shown to infect
virtually all of the hepatocytes (4), and groups of four mice
were killed on days 3, 7, 14, 21, and 24 after infection (Ta-
ble I). Additionally, 13 C57BL/6 mice were injected intra-
peritoneally with recombinant murine IL-12 (1 mg/d) for
either 3 or 10 d, and all animals were killed 24 h after the
last injection (Table I). Results were compared with saline-
injected controls as indicated in Table I. These treatments
were chosen because they are known to induce IFN type I,
IFN-g, and TNF-a in the liver either with (adenovirus) or
without (IL-12) destroying hepatocytes (2, 4). As expected,
the adenovirus-infected animals developed a necroinflamma-
tory liver disease that was detectable histologically (not
shown) and biochemically as elevated sALT activity (Table I)
starting between 3 and 7 d after inoculation and lasting z3
wk until lacZ-positive hepatocytes were no longer detectable
(not shown). Despite the relatively severe liver disease (com-
pared with that induced by transfer of memory cells), the vi-
ral titers in the serum, liver, and spleen did not change at any
of the time points examined (Table I). Similarly, no change
in viral titer was observed in the IL-12–treated animals in
which we observed no biochemical (Table I) and/or histo-
logical evidence of liver cell injury (not shown). The absence
of viral clearance in the livers of adenovirus-infected and IL-
12–injected mice was also confirmed by Northern blot anal-
ysis of LCMV RNA, as shown in Figs. 5 and 7.
Because these results appeared to contradict the results of
the memory cell transfer experiments, we performed in situ
hybridization analyses on the adenovirus-infected and IL-12–
injected livers to examine the hepatic distribution of LCMV
RNA. Surprisingly, LCMV RNA was dramatically reduced
in the hepatocytes (but not in nonparenchymal cells, which
include resident nonparenchymal cells and infiltrating in-
flammatory cells) by days 7 (Fig. 6 B) and 14 (not shown) af-
ter adenovirus infection, concomitant with the induction of
cytokines in the liver (Fig. 5). In contrast, the intensity and
distribution of grains in the hepatocytes on day 24 after ade-
novirus infection (Fig. 6 C) were similar to those of saline-
injected controls (Fig. 6 A), and this occurred at a time point
when the liver disease and the adenoviral infection had re-
solved (not shown) and the cytokines were no longer in-
duced in the liver (Fig. 5). Similarly, LCMV RNA disap-
peared from the hepatocyte (but not from nonparenchymal
cells) after 3 (Fig. 8, B–F) or 10 (not shown) IL-12 injec-
tions, and this occurred in livers in which there was inflam-
matory cell infiltration but little or no histological evidence
of hepatocyte injury (not shown) or sALT elevation (Table
I). Collectively, these results indicate that LCMV is rapidly
cleared from the hepatocyte in a bystander manner concom-
itant with intrahepatic cytokine induction, and this effect is
not dependent on the destruction of hepatocytes.
Lack of Clearance of Persistent LCMV Infection from Intrahe-
patic Nonparenchymal Cells and from Splenocytes after Adenovi-
rus Infection or IL-12 Administration. As shown in Figs. 6 and
Figure 6. Intrahepatic distribution of LCMV RNA after adenovirus infection. The same livers described in the legend to Fig. 5 were analyzed for the
expression of LCMV RNA by in situ hybridization using a specific 33P-labeled LCMV riboprobe. (A) Detection of hepatic LCMV mRNAs in saline-
injected control mice. (B) Detection of hepatic LCMV mRNAs in mice injected with adenovirus and killed at day 7. Note that LCMV RNA is virtually
no longer detectable in the hepatocytes but remains in nonparenchymal and inflammatory cells (arrows). (C) Detection of hepatic LCMV mRNAs in
mice injected with adenovirus and killed at day 24. Note that most LCMV RNA is detected in the hepatocytes, similar to saline-injected controls shown
in A (hematoxylin and eosin; original magnification: 3600).1561 Guidotti et al.
8, the local induction of cytokines observed after adenovi-
rus infection and IL-12 administration was not associated
with clearance of LCMV RNA from nonparenchymal liver
cells or the spleen. This probably explains why the virus
was not eliminated from these organs or the serum as mea-
sured by plaque assay (Table I). Indeed, the number of
splenocytes positive for LCMV RNA by in situ hybridiza-
tion was similar in the saline-injected controls and in mice
injected with IL-12 (not shown), despite the fact that the
cytokines were strongly induced in these organs (not
shown). Collectively, these results indicate that LCMV
clearance from nonparenchymal cells does not occur in the
absence of a LCMV-specific immune response, suggesting
that other mechanisms are probably required to clear the
virus from these cells.
LCMV Variants Are Selected in Persistently Infected Livers
and They Are Not Eliminated from Intrahepatic Nonparenchymal
Cells after Adenovirus Infection or IL-12 Administration. Af-
ter neonatal infection with LCMV ARM, variants such as
clone 13, which are known to be more resistant to control
by IFNs (11), have been isolated from persistently infected
livers (23). To test whether these variants are present in the
livers of control mice (in which most viral RNA is in the
hepatocytes) and IL-12–treated or adenovirus-infected mice
(in which most viral RNA is in the nonparenchymal cells),
we performed a PCR assay for the detection of a point
mutation in the viral RNA that results in a phenylalanine
versus a leucine change at position 260 in the viral glyco-
protein (23). The phenylalanine/leucine change is diagnos-
tic for the ARM strain of LCMV versus variants such as
clone 13. Roughly equimolar amounts of RNA encoding a
phenylalanine versus a leucine residue were detected in the
liver of saline-injected controls and IL-12–treated or aden-
ovirus-infected mice (not shown). This suggests that the
ARM as well as the variant strains of LCMV are resistant to
the antiviral effects induced by IL-12 or adenovirus when
they replicate in the nonparenchymal cells. Whether the
hepatocytes were infected with ARM or the variant strains
or both, and whether these viruses would be differently
sensitive to clearance by IL-12 injection or adenovirus in-
fection, remain to be determined.
Discussion
In this study, we demonstrate that LCMV can be cleared
from hepatocytes by noncytopathic, cytokine-associated
antiviral mechanisms that are not operative in splenocytes
or in nonparenchymal cells (which include resident non-
parenchymal cells and infiltrating inflammatory cells) in the
liver. Several lines of evidence support these conclusions.
After transfer of memory cells, viral clearance from the
hepatocytes occurs very rapidly, between 3 and 7 d after
transfer and 4 d (or less) after the peak of LCMV replica-
tion (Table I). This is associated with a relatively mild liver
disease, and it occurs in the context of intrahepatic cyto-
kine induction. Indeed, the liver disease in these animals
would probably be much more severe if viral clearance was
due primarily to the destruction of the infected cells, based
on comparison with previously reported mouse models of
liver disease (1, 26). Conversely, viral clearance from the
intrahepatic nonparenchymal cells and from the spleen of
the same animals is a much slower process that follows the
peak of local cytokine induction by .10 d, suggesting ei-
ther that these cells are less responsive to cytokines or that
other events, including killing, are required to clear the vi-
rus from these cell types. Furthermore, LCMV clearance
from the hepatocytes (but not from the intrahepatic non-
parenchymal cells and from the spleen) can also occur
when cytokines are locally induced after adenovirus infec-
Figure 7. Intrahepatic LCMV, T cell marker, and cytokine gene ex-
pression after IL-12 administration. Age- and serum LCMV titer–matched
C57BL/6 mice were injected intraperitoneally either with saline or with
IL-12 (1 mg/d/mouse) and killed on day 3 after injection, as indicated.
Northern blot (NB) analysis (top panel) was performed with 20 mg of to-
tal liver RNA from two representative mice per group. The membrane
was hybridized with 32P-labeled LCMV-, 2959 OAS– (a marker of IFN-
a/b induction), and GAPDH-specific DNA probes. Total hepatic RNA
(10 mg) from the same mice was also analyzed by RNase protection assay
(RPA) for the expression of various cytokine transcripts, and for the ex-
pression of CD3, CD4, CD8, and F480, as indicated. The mRNA en-
coding the ribosomal protein L32 was used to normalize the amount of
RNA loaded in each lane. The results of the plaque assay (PFU per gram)
of individual liver tissues are also indicated.1562 Noncytopathic Clearance of LCMV
tion or IL-12 administration. Again, this effect occurs rap-
idly (by day 3 for IL-12 and by day 7 for adenovirus), con-
comitant with the peak of intrahepatic cytokine induction
and, in the case of IL-12, independently of hepatocyte de-
struction. This strongly suggests that cytokines can activate
intracellular antiviral pathways in the hepatocytes (but not
in the intrahepatic nonparenchymal cells or in the spleen).
In support of this hypothesis, LCMV RNA reappears in
the hepatocytes of adenovirus-infected and IL-12–injected
animals when the intrahepatic cytokine induction subsided,
in contrast to the memory cell recipients. This is presum-
ably due to the absence of anti-LCMV antibodies and
LCMV-specific T cells in the adenovirus-infected and IL-
12–injected animals, since both B and T cells are required
to clear a persistent LCMV infection (27).
These results indicate that cytokine-dependent activation
of hepatocytes triggers intrahepatocellular antiviral events
that are absent or not operative in certain other cell types.
This is reminiscent of the unique role that hepatocytes play
in host defense mechanisms after tissue damage. Indeed,
Figure 8. Intrahepatic distribution of LCMV RNA after IL-12 administration. The same livers described in the legend to Fig. 7 were analyzed for the
expression of LCMV RNA by in situ hybridization using a specific 33P-labeled LCMV riboprobe. (A) Detection of hepatic LCMV mRNAs in saline-
injected control mice. (B–F) Detection of hepatic LCMV mRNAs in mice injected with IL-12. Note that LCMV RNA is virtually no longer detectable
in the hepatocytes but remains in nonparenchymal and inflammatory cells (hematoxylin and eosin; original magnification: 3600).1563 Guidotti et al.
during the acute phase response, the interaction of a wide
variety of cytokines (including IFN-g, IL-1a, IL-1b, IL-6,
TNF-a, and TNF-b), glucocorticoids, and growth factors
with hepatocytes results in a complex response character-
ized by activation of the acute phase plasma proteins (APPs)
and profound changes in most metabolic pathways (28).
The regulation of APP gene expression depends on tran-
scriptional and posttranscriptional events (28) that are most
likely operative in hepatocytes but not in nonhepatic cells.
This study indicates that cytokines may activate hepatic
cells not only to regulate APP genes but also to induce cell-
specific antiviral pathways.
It has been suggested that specific destruction of infected
cells (including hepatocytes) is required to control LCMV
replication in the liver and other organs, since perforin-
deficient mice fail to clear acute LCMV infection (6, 7).
However, it is important to note that LCMV clearance was
monitored by plaque assay in those studies which might
not have detected the selective clearance of LCMV from
the hepatocytes. Experiments designed to monitor the cy-
tokine profile and the cellular distribution of viral RNA in
the liver of these animals are needed to examine the possi-
bility that LCMV clearance may have occurred from the
hepatocytes but not from nonparenchymal cells in the per-
forin-deficient mice, as we observed after adenoviral infec-
tion and IL-12 administration. Indeed, we have previously
shown that 2 d after acute LCMV infection, most of the
virus replicates within nonparenchymal cells rather than
hepatocytes (3). In addition, passive transfer of IFN-g–defi-
cient memory cells into persistently LCMV ARM–infected
animals fails to clear the virus in liver and spleen (14), and
mice genetically deficient for IFN-g or its receptor have
been shown to control LCMV replication less efficiently in
various organs, including the liver, despite normal immune
responses (8). Finally, in vivo treatment of neutralizing an-
tibodies to this cytokine results in higher levels of LCMV
replication during acute infection (11).
In conclusion, the results of this report show that
LCMV, like HBV, is susceptible to noncytopathic antiviral
control mechanisms that most likely depend on local cy-
tokine induction, provided that the virus replicates within
the hepatocyte. We have recently shown that HBV replica-
tion is completely abolished in the hepatocytes of HBV
transgenic mice by cytokine-dependent pathways that do
not require cell death (29), and that intrahepatic induction
of the IFNs and TNF-a mediates the antiviral effect (1), ir-
respective of the stimuli that trigger their induction.
Whether similar intracellular events may interfere with the
life cycle of additional viruses remains to be determined.
Nevertheless, viral clearance of these and other viruses
might rely very heavily on noncytopathic curative mecha-
nisms, especially for viruses that infect a large number of
parenchymal cells in vital organs, like the liver. Indeed, it
has been recently suggested that the control of murine
CMV infection in the liver may depend on IFN-g–depen-
dent noncytopathic mechanisms (30). Conversely, viral
clearance from nonparenchymal cells might rely mostly on
immune-mediated cytodestructive mechanisms.
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